plerixafor has been researched along with Recrudescence in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Armand, P; Azab, AK; Basile, F; Baz, R; Boruchov, A; Chuma, S; Constantine, M; Crilley, P; Ghobrial, IM; Henrick, PM; Hornburg, KTV; Laubach, JP; Leblebjian, H; Liu, CJ; Mishima, Y; Munshi, NC; Noonan, K; Paba-Prada, C; Reyes, K; Richardson, PG; Schlossman, R; Shain, K; Trippa, L; Vredenburgh, J; Warren, D; Weller, E; Zavidij, O | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Elhamri, M; Hayette, S; Heiblig, M; Plesa, A; Raffoux, E; Thomas, X | 1 |
| Choi, J; Cross, SJ; Dallas, MH; Hartford, C; Jacobsen, J; Kang, G; Leung, W; Panetta, JC; Pillai, A; Shook, DR; Srinivasan, A; Sunkara, A; Triplett, BM | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Bornhäuser, M; Brenner, S; Ehninger, G; Fierro, FA; Illmer, T; Jacobi, A; Knoth, H; Oelschlaegel, U | 1 |
| Anthony, K; Dalal, J; Flatt, T; Gamis, A; Gonzalez, C; Jones, R; Lewing, K; Ryan, R | 1 |
| DiPersio, JF; Fruehauf, S; Hanrahan, J; Ho, AD; Hsu, FJ | 1 |
| Bernardo, VA; Joyce, MJ; Ng, JS | 1 |
| Basak, GW; Basic-Kinda, S; Giebel, S; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Akay, C; Badel, K; Calandra, G; Freytes, CO; Gazitt, Y | 1 |
1 review(s) available for plerixafor and Recrudescence
| Article | Year |
|---|---|
Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Biomarkers, Tumor; Combined Modality Therapy; Cyclams; Cytokines; DNA, Neoplasm; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Neoplasm, Residual; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Recurrence; Risk; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2011 |
6 trial(s) available for plerixafor and Recrudescence
| Article | Year |
|---|---|
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Bone Marrow; Bortezomib; Combined Modality Therapy; Cyclams; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Receptors, CXCR4; Recurrence; Salvage Therapy; Tumor Microenvironment | 2019 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Benzylamines; Cyclams; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 2018 |
Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Topics: Benzylamines; Biomarkers, Pharmacological; Cyclams; Female; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia; Male; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2014 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Topics: Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Benzylamines; Cyclams; Dendritic Cells; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neutrophils; Patient Selection; Receptors, CXCR4; Recurrence; Tissue Preservation; Transplantation Conditioning; Treatment Outcome | 2007 |
4 other study(ies) available for plerixafor and Recrudescence
| Article | Year |
|---|---|
Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, CXCR4; Recurrence | 2009 |
Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Burkitt Lymphoma; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Recurrence; Treatment Outcome | 2010 |
Use of Plerixafor with Granulocyte Colony-Stimulating Factor for Stem Cell Mobilization in a Pediatric Patient.
Topics: Benzylamines; Child; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Recurrence | 2011 |
Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Recombinant Proteins; Recurrence; Retrospective Studies; Transplantation, Autologous | 2011 |